Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azolen Anti-Fungal Wash is an over-the-counter (OTC) topical antifungal product developed and marketed by Stratus Pharmaceuticals. The formulation contains 2% miconazole nitrate, an imidazole-class antifungal agent. Miconazole works by inhibiting the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the biosynthesis of ergosterol, a critical component of fungal cell membranes. The resulting depletion of ergosterol and accumulation of methylated precursors lead to the disruption of fungal cell membrane integrity and function, ultimately inhibiting fungal growth. Azolen is specifically indicated for the treatment of common cutaneous fungal infections, including athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). It is designed as a wash to be applied to affected areas during showering to relieve symptoms such as itching, scaling, cracking, burning, and redness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azolen Anti-Fungal Wash.